Mir195 enables Ebf1-deficient hematopoietic progenitor cells to mature into B cells, suggesting some miRNA can substitute for transcription factors in differentiation.

In a milestone for the hematologic oncology landscape, the first patient has been dosed in a phase 1/2 clinical trial (NCT07220616) evaluating DS3790, a potential first-in-class antibody-drug ...

The new version of CAR-T therapy has shown the ability to effectively destroy cancer cells in mice without suppressing the ...

The essential B vitamin folic acid is needed by our bodies in much smaller amounts than macronutrients such as protein. However, micronutrients are crucial for the complex interactions within our ...

Upregulated expression of transcription factors promoting cone identity in late-stage retinal progenitors drives development ...

Researchers developed a mouse model of multiple sclerosis that captures the features of progression independent of relapse ...

Detailed price information for Tg Therapeutics (TGTX-Q) from The Globe and Mail including charting and trades.

In this interview, Technology Networks spoke to Dr. Funda Meric-Bernstam about the landscape of personalized cancer therapy.

After raising $61 million in a series B round, Vibrant Therapeutics Inc. is gearing up to begin a U.S. phase I trial with its lead program, VIB-305, a masked T-cell engager (TCE) for treating ...

It’s been spruiked as everything from cutting-edge science to an unethical wasteland masquerading as healthcare.

Emerging research has provided fresh evidence regarding the role of viral infection in the development of multiple sclerosis.

Immunic presents additional phase 2 CALLIPER trial data for vidofludimus calcium in patients with progressive MS at the ACTRIMS Forum 2026: New York Friday, February 6, 2026, 16:0 ...